Background: Galectin-3 (Gal-3) is an emerging biomarker in heart failure that is involved in fibrosis and inflammation. However, its potential value as a prognostic marker in atrial fibrillation (AF) is unknown. The aim of this study was to assess the impact of AF catheter ablation on Gal-3 and evaluate its prognostic impact for predicting rhythm outcome after catheter ablation. Methods: Gal-3 was measured at baseline and after 6 months using specific ELISA. AF recurrences were defined as any atrial arrhythmia lasting longer than 30 sec within 6 months after ablation. Results: In 105 AF patients (65% males, age 62±9 years, 52% paroxysmal AF) undergoing catheter ablation, Gal-3 was measured at baseline and after 6 months and compared with an AF-free control cohort (n=14, 50% males, age 58±11 years). Gal-3 was higher in AF patients compared with AF-free controls (7.8± 2.9 vs. 5.8±1.8, ng/mL, p=0.013). However, on multivariable analysis, BMI (p=0.007) but not AF (p=0.068) was associated with Gal-3. In the AF cohort, on univariable analysis higher Gal-3 levels were associated with female gender (p=0.028), higher BMI (p=0.005) and both CHADS2 (p=0.008) and CHA2DS2-VASC (p=0.016) scores, however, on multivariable analysis only BMI remained significantly associated with baseline Gal-3 (p=0.016). Gal-3 was similar 6 months after AF catheter ablation and was not associated with sinus rhythm maintenance. Conclusions: Although galectin-3 levels are higher in AF patients, this is driven by cardiometabolic comorbidities and not heart rhythm. Gal-3 is not useful for predicting rhythm outcome of catheter ablation.
CITATION STYLE
Kornej, J., Schmidl, J., Ueberham, L., John, S., Daneschnejad, S., Dinov, B., … Bollmann, A. (2015). Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. PLoS ONE, 10(4). https://doi.org/10.1371/journal.pone.0123574
Mendeley helps you to discover research relevant for your work.